Literature DB >> 31665763

Risk factors for development of aminoglycoside resistance among gram-negative rods.

Stefan E Richter1, Loren Miller2, Jack Needleman3, Daniel Z Uslan4, Douglas Bell5, Karol Watson1, Romney Humphries6, James A McKinnell7.   

Abstract

PURPOSE: Development of scoring systems to predict the risk of aminoglycoside resistance and to guide therapy is described.
METHODS: Infections due to aminoglycoside-resistant gram-negative rods (AR-GNRs) are increasingly common and associated with adverse outcomes; selection of effective initial antibiotic therapy is necessary to reduce adverse consequences and shorten length of stay. To determine risk factors for AR-GNR recovery from culture, cases of GNR infection among patients admitted to 2 institutions in a major academic hospital system during the period 2011-2016 were retrospectively analyzed. Gentamicin and tobramycin resistance (GTR-GNR) and amikacin resistance (AmR-GNR) patterns were analyzed separately. A total of 26,154 GNR isolates from 12,516 patients were analyzed, 6,699 of which were GTR, and 2,467 of which were AmR.
RESULTS: In multivariate analysis, risk factors for GTR-GNR were presence of weight loss, admission from another medical or long-term care facility, a hemoglobin level of <11 g/dL, receipt of any carbapenem in the prior 30 days, and receipt of any fluoroquinolone in the prior 30 days (C statistic, 0.63). Risk factors for AmR-GNR were diagnosis of cystic fibrosis, male gender, admission from another medical or long-term care facility, ventilation at any point prior to culture during the index hospitalization, receipt of any carbapenem in the prior 30 days, and receipt of any anti-MRSA agent in the prior 30 days (C statistic, 0.74). Multinomial and ordinal models demonstrated that the risk factors for the 2 resistance patterns differed significantly.
CONCLUSION: A scoring system derived from the developed risk prediction models can be applied by providers to guide empirical antimicrobial therapy for treatment of GNR infections. © American Society of Health-System Pharmacists 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  aminoglycosides; antimicrobial resistance; antimicrobial stewardship; clinical decision making; gram-negative rods

Mesh:

Substances:

Year:  2019        PMID: 31665763      PMCID: PMC7170722          DOI: 10.1093/ajhp/zxz201

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  28 in total

1.  Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay.

Authors:  Andrew F Shorr; Scott T Micek; Emily C Welch; Joshua A Doherty; Richard M Reichley; Marin H Kollef
Journal:  Crit Care Med       Date:  2011-01       Impact factor: 7.598

2.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.

Authors:  Anand Kumar; Daniel Roberts; Kenneth E Wood; Bruce Light; Joseph E Parrillo; Satendra Sharma; Robert Suppes; Daniel Feinstein; Sergio Zanotti; Leo Taiberg; David Gurka; Aseem Kumar; Mary Cheang
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

3.  A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.

Authors:  Carl van Walraven; Peter C Austin; Alison Jennings; Hude Quan; Alan J Forster
Journal:  Med Care       Date:  2009-06       Impact factor: 2.983

4.  Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

Authors:  Melinda M Neuhauser; Robert A Weinstein; Robert Rydman; Larry H Danziger; George Karam; John P Quinn
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

5.  Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.

Authors:  Ronald E Polk; Christopher K Johnson; Donna McClish; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-08-02       Impact factor: 9.079

6.  Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex.

Authors:  Evelina Tacconelli; Maria Adriana Cataldo; Gennaro De Pascale; Daniela Manno; Teresa Spanu; Andrea Cambieri; Massimo Antonelli; Maurizio Sanguinetti; Giovanni Fadda; Roberto Cauda
Journal:  J Antimicrob Chemother       Date:  2008-07-17       Impact factor: 5.790

Review 7.  Aminoglycosides: how should we use them in the 21st century?

Authors:  Justin Jackson; Caroline Chen; Kirsty Buising
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

8.  Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia.

Authors:  Andrew F Shorr; Marya D Zilberberg; Scott T Micek; Marin H Kollef
Journal:  Arch Intern Med       Date:  2008-11-10

Review 9.  Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis.

Authors:  Gowri Raman; Esther Avendano; Samantha Berger; Vandana Menon
Journal:  BMC Infect Dis       Date:  2015-09-30       Impact factor: 3.090

10.  Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas Aeruginosa.

Authors:  Kosuke Kosai; Norihito Kaku; Naoki Uno; Tomomi Saijo; Yoshitomo Morinaga; Yoshifumi Imamura; Hiroo Hasegawa; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Mukae; Katsunori Yanagihara
Journal:  Open Microbiol J       Date:  2017-05-31
View more
  1 in total

1.  Identifying alternative antibiotics that elute from calcium sulfate beads for treatment of orthopedic infections.

Authors:  Ashley E Levack; Kathleen Turajane; Daniel A Driscoll; Xu Yang; Andy O Miller; Mathias P Bostrom; David S Wellman; Alberto V Carli
Journal:  J Orthop Res       Date:  2021-07-12       Impact factor: 3.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.